Abstract
Quantitation of metabolic changes in tumours may provide an objective measure of clinical and subclinical response to anticancer therapy. This pilot study assesses the value of quantitation of metabolic rate of glucose (MRGlu) measured in mmol min–1ml–1to assess early subclinical response to therapy in a relatively non-responsive tumour. Nine patients receiving the CRC Phase II study schedule of temozolomide were assessed with [18F]fluorodeoxyglucose ([18F]FDG) dynamic positron emission tomography (PET) scans prior to and 14 days after treatment with temozolomide given as 750–1000 mg m–2over 5 days every 28 days. Tumour MRGlu was calculated and compared with objective response at 8 weeks. Pretreatment MRGlu was higher in responders than non-responders. The responding patient group had a greater than 25% reduction in MRGlu in regions of high focal tumour uptake (HFU). Whole tumour changes in MRGlu did not correlate with response. Percentage change in HFU standardized uptake value (SUV) did discriminate the responding from the non-responding patients, but not as well as with MRGlu. Large differences also occurred in the normal brain SUV following treatment. Thus, MRGlu appeared to be a more sensitive discriminator of response than the simplified static SUV analysis. Changes in MRGlu may reflect the degree of cell kill following chemotherapy and so may provide an objective, quantitative subclinical measure of response to therapy.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Alavi JB, Alavi A, Chawluk J, Kushner M, Powe J, Hickey W and Reivich M (1988) Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer 62: 1074–1078
Bennett MJ, Timperley WR, Taylor CB and Hill AS (1978) Isoenzymes of hexokinase in the developing, normal and neoplastic human brain. Eur J Cancer 14: 189–193
Bland JM and Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1: 307–310
Blasberg RG, Groothuis DR and Molnar P (1981) The application of qualitative autoradiographic measurements in experimental brain tumours. Semin Neurol 1: 203–333
Bleehen NM, Freedman LS and Stenning SP (1989) A randomized study of CCNU with and without benznidazole in the treatment of recurrent grades 3 and 4 astrocytoma. Report to the Medical Research Council by the Brain Tumor Working Party. Int J Radiat Oncol Biol Phys 16: 1077–1081
Brown RS and Wahl RL (1993) Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer 72: 2979–2985
Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP and Wahl RL (1996) Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between Glut-1 expression and FDG uptake. J Nucl Med 37: 1042–1047
Cairncross JG, Pexman JH, Rathbone MP and DelMaestro RF (1985) Postoperative contrast enhancement in patients with brain tumor. Ann Neurol 17: 570–572
Cairncross JG, Macdonald DR, Pexman JH and Ives FJ (1988) Steroid-induced CT changes in patients with recurrent malignant glioma. Neurology 38: 724–726
De Witte O, Hildebrand J, Luxen A and Goldman S (1994) Acute effect of carmustine on glucose metabolism in brain and glioblastoma. Cancer 74: 2836–2842
Di Chiro G, DeLaPaz RL, Brooks RA, Sokoloff L, Kornblith PL, Smith BH, Patronas NJ, Kuff GCV, Kessler RM, Johnson GS, Manning RG and Wolf AP (1982) Glucose utilization of cerebral gliomas measured by [18F]- fluorodeoxyglucose and positron emission tomography. Neurology 32: 1323–1329
Fischman AJ and Alpert NM (1993) FDG-PET in oncology: there's more to it than looking at pictures. J Nucl Med 34: 6–11
Fulham MJ, Brunetti A, Aloj L, Raman R, Dwyer AJ and Di Chiro G (1995) Decreased cerebral glucose metabolism in patients with brain tumours: an effect of cortocosteroids. J Neurosurg 83: 657–664
Hamacher K, Coenen HH and Stocklin G (1986) Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 27: 235–238
Hamberg LM, Hunter GJ, Alpert NM, Choi NC, Babich JW and Fischman AJ (1994) The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification?. J Nucl Med 35: 1308–1312
Herholz K, Wienhard K and Heiss WD (1990) Validity of PET studies in brain tumors. Cerebrovasc Brain Metab Rev 2: 240–265
Herholz K, Rudolf J and Heiss WD (1992) FDG transport and phosphorylation in human gliomas measured with dynamic PET. J Neurosurg 12: 159–165
Herholz K, Pietrzyk U, Voges J, Schroder R, Halber M, Treuer H, Sturm V and Heiss WD (1993) Correlation of glucose consumption and tumour cell density in astrocytomas. A stereotactic PET study. J Neurosurg 79: 853–858
Higashi K, Clavo AC and Wahl RL (1993) Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake [see comments]. J Nucl Med 34: 414–419
Holthoff VA, Herholz K, Berthold F, Widemann B, Schroder R, Neubauer I and Heiss WD (1993) In vivo metabolism of childhood posterior fossa tumors and primitive neuroectodermal tumors before and after treatment. Cancer 72: 1394–1403
Huang SC, Phelps ME, Hoffman EJ, Sideris K, Selin CJ and Kuhl DE (1980) Noninvasive determination of local cerebral metabolic rate of glucose in man. Am J Physiol 238: E69–82
Ichiya Y, Kuwabara Y and Otsuka M (1991) Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography. J Nucl Med 32: 1655–1660
Ishizu K, Nishizawa S, Yonekura Y, Sadato N, Magata Y, Tamaki N, Tsuchida T, Okazawg H, Miyatake S and Ishikawa M (1994) Effects of hyperglycemia on FDG uptake in human brain and glioma [see comments]. J Nucl Med 35: 1104–1109
Jansson T, Westlin JE, Ahlstrom H, Lila A, Langstrom B and Bergh J (1995) Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation?. J Clin Oncol 13: 1470–1477
Lammertsma AA, Brooks DJ, Frackowiak RS, Beaney RP, Herold S, Heather JD, Palmer AJ and Jones T (1987) Measurement of glucose utilisation with [18F]2-fluoro-2-deoxy-D-glucose: a comparison of different analytical methods. J Cereb Blood Flow Metab 7: 161–172
Lindholm P, Minn H, Leskinen KS, Bergman J, Ruotsalainen U and Joensuu H (1993) Influence of the blood glucose concentration on FDG uptake in cancer – a PET study [see comments]. J Nucl Med 34: 1–6
Minn H, Joensuu H, Ahonen A and Klemi P (1988a) Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumours. Cancer 61: 1776–1781
Minn H, Paul R and Ahonen A (1988b) Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18 fluorodeoxyglucose. J Nucl Med 29: 1521–1525
Newlands ES, Blackledge GR, Slack JA, Rustin GJ, Smith DB, Stuart NS, Quarterman CP, Hoffman R, Stevens MF, Brampton MH and Gibson AC (1992) Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 65: 287–291
Okada J, Yoshikawa K, Itami M, Imaseki K, Uno K, Itami J, Kuyama J, Mikata A and Arimizu N (1992) Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 33: 325–329
O'Reilly SM, Newlands ES, Glaser MG, Brampton M, Rice Edwards JM, Illingworth RD, Richards P, Kennard C, Colquhoun T and Lewis P (1993) Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours [published erratum appears in Eur J Cancer 29a: 1500]. Eur J Cancer 29a: 940–942
Patronas NJ, Di Chiro G, Brooks RA, DeLaPaz RL, Kornblith PL, Smith BH, Rizzoli HV, Kessler RM, Manning RG, Channing M, Wolf AP and O'Connor CM (1982) Work in progress: [18F]fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. Radiology 144: 885–889
Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L and Kuhl DE (1979) Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 6: 371–388
Price P and Jones T (1995) Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? The EC PET Oncology Concerted Action and the EORTC PET Study Group. Eur J Cancer 31a: 1924–1927
Ranicar AS, Williams CW, Schnorr L, Clark JC, Rhodes CG, Bloomfield PM and Jones T (1991) The on-line monitoring of continuously withdrawn arterial blood during PET studies using a single BGO/photomultiplier assembly and non-stick tubing. Med Prog Technol 17: 259–264
Reivich M, Alavi A, Wolf A, Fowler J, Russell J, Arnett C, MacGregor RR, Shive CY, Atkins H, Anand A, Dann R and Greenberg JH (1985) Glucose metabolic rate kinetic model parameter determination in humans: the lumped constants and rate constants for [18F]fluorodeoxyglucose and [11C]deoxyglucose. J Cereb Blood Flow Metab 5: 179–192
Roelcke U, Blasberg RG, von Ammor K, Hofer S, Vontobel P, Maguire RP, Radii EW, Herman RP and Leenders KL (1998) Dexamethasone treatment and plasma glucose values: relevance for fluorine-18-fluorodeoxyglucose uptake measurements in gliomas. J Nucl Med 39: 879–884
Rozental JM, Levin RL, Nickles RJ and Dobkin JA (1989) Glucose uptake by gliomas after treatment. A positron emission tomographic study [see comments]. Arch Neurol 46: 1302–1307
Schmidt K, Lucignani G, Moresco RM, Rizzo G, Gilardi MC, Messa C, Colombo F, Fazio F and Sokoloff L (1992) Errors introduced by tissue heterogeneity in estimation of local cerebral glucose utilization with current kinetic models of the [18F]fluorodeoxyglucose method. J Cereb Blood Flow Metab 12: 823–834
Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, Sakurada O and Shinohara M (1977) The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 28: 897–916
Spence AM, Muzi M and Graham MM (1998) Glucose metabolism in human malignant gliomas measured quantitatively with PET, 1-[C-11]Glucose and FDG: analysis of the FDG lumped constant. J Nucl Med 39: 440–448
Valk PE, Budinger TF, Levin VA, Silver P, Gutin PH and Doyle WL (1988) PET of malignant cerebral tumors after interstitial brachytherapy. Demonstration of metabolic activity and correlation with clinical outcome. J Neurosurg 69: 830–838
Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B and Cody R (1993) Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 11: 2101–2111
Woods RP, Cherry SR and Mazziotta JC (1992) Rapid automated alogorithm for aligning and reslicing PET images. J Comput A Tomogr 16: 620–633
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Brock, C., Young, H., O'Reilly, S. et al. Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography:a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas. Br J Cancer 82, 608–615 (2000). https://doi.org/10.1054/bjoc.1999.0971
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.1999.0971
Keywords
This article is cited by
-
Dynamic susceptibility contrast and diffusion MR imaging identify oligodendroglioma as defined by the 2016 WHO classification for brain tumors: histogram analysis approach
Neuroradiology (2019)
-
Modification of loco-regional microenvironment in brain tumors by spinal cord stimulation. Implications for radio-chemotherapy
Journal of Neuro-Oncology (2012)
-
F-18 FDG PET-CT for predicting survival in patients with recurrent glioma: a prospective study
Neuroradiology (2011)